The University System of Maryland (USM) has named Claire Broido Johnson, MBA, as Managing Director of the Maryland Momentum Fund (MMF), a $10 million investment fund that supports early-stage companies affiliated with USM institutions. She joins the USM this week.
Anne Lindblad, PhD, joined Emmes in 1982 as a Biostatistician and currently serves as the President and CEO of the company. She has supported clinical research throughout her career, serving as Principal Investigator of projects spanning diverse disease areas, including neurology, ophthalmology, oncology, dialysis, transplantation, speech and hearing, and dentistry.
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option valued at $261 million to procure doses of AV7909 (anthrax vaccine adsorbed with adjuvant) for delivery into the Strategic National Stockpile (SNS) over 12 months. This contract option was exercised under the company’s 2016 development and procurement contract with BARDA, valued at up to $1.5 billion, that includes a five-year base period of performance to develop AV7909 for post-exposure prophylaxis of anthrax disease and to deliver an initial three million doses to the SNS, as well as contract options for procurement of up to an additional 50 million doses. This exercise of the contract option through a modification is the first such option for procurement of doses to follow the initial deliveries of doses under the base contract.
The Johns Hopkins Hospital is once again ranked #3 in the nation out of more than 4,600 hospitals reviewed for U.S. News & World Report’s 2019–20 Best Hospitals list, which was released today.
Mayo Clinic and medical device giant Boston Scientific are slated to announce a new med-tech accelerator Monday.
The collaboration will be located in One Discovery Square, a new building in Rochester adjacent to Mayo Clinic that’s meant to attract medical technology startups.
The U.S. Economic Development Administration awarded more than $600,000 to a division of Johns Hopkins University on Tuesday to increase economic development in the region’s digital health field.
gel-e is developing a line of advanced hemostatic and wound treatment products that address unmet needs from the operating room to the backyard. Following previous clearances for topical and external use of its platform technology (see http://www.gel-e.co/news.html), the Company is now expanding its label to include use for internal and surgical applications. The first product, now on an accelerated path as a Breakthrough Device, is an expanding injectable hemostat, Life Foam™. Life Foam can rapidly provide temporary control of bleeding from non-compressible abdominal wounds that are not amenable to tourniquet application in trauma and battlefield conditions. As the tradename suggests, this product is designed to save the lives of those injured in battle, or that are the victims of traumatic accidents or even terrorist attacks.
In the last five to 10 years, it would seem as though Baltimore is finally emerging (at least economically) — from its slow, multi-decade decline. But if you’re a resident of one of the city’s poorer neighborhoods, you might not know it.
A nice, relaxing glass of Bordeaux or Cabernet might easily seem like the perfect treatment for an anxious or slightly depressed state. Though, the alcohol might lead one down a slippery path rather quickly. Instead, investigators at the University of Buffalo (UB) and Xuzhou Medical University in China have decided to focus their attention on the widely studied plant compound—found in considerably higher levels in red wine than most other plants—called resveratrol. This phenolic compound has been studied for several decades, in connection with reduced incidence of cardiovascular disease and for the treatment of cancer, with mixed results. Yet now, researchers found new evidence of resveratrol displaying anti-stress effects by blocking the expression of an enzyme related to the control of stress in the brain.
A patent granted to George Mason University Research Foundation Inc., which describes a novel treatment method for pre-invasive breast cancer, has been exclusively licensed to Targeted Pharmaceuticals LLC, a clinical-stage biopharmaceutical company focused on utilizing cannabinoids for the treatment of oncology and central nervous system disorders.
